For diabetes drug Avandia, bad news continues

Two new studies link the drug to increased heart risks just weeks before the FDA will consider whether it should remain on the market. The diabetes drug Avandia, once the world's top-selling diabetes medication, took two more hits Monday with one new study linking it to an increased risk of heart attacks and a separate study linking it to an increased risk of...

Read the whole article on LA Times - Health

More from LA Times - Health